SMYD3 and breast carcinoma: The methyltransferase SET and MYND domain-containing protein 3 (SMYD3) enables H2A.Z1 methylation, thereby reducing the removal of H2A.Z1 from chromatin by Anp32e, increasing cell cycle-related protein expression, and promoting breast cancer cell proliferation [37].